iBio, Inc. (IBIO)
$0.2604
Rating:
Recommendation:
Buy
| Symbol | IBIO |
|---|---|
| Price | $0.2604 |
| Beta | -4.648 |
| Volume Avg. | 3.05M |
| Market Cap | 56.810M |
| Shares () | - |
| 52 Week Range | 0.22-1.46 |
| 1y Target Est | - |
| DCF Unlevered | IBIO DCF -> | |
|---|---|---|
| DCF Levered | IBIO LDCF -> | |
| ROE | -12.95% | Sell |
| ROA | -10.64% | Sell |
| Operating Margin | - | |
| Debt / Equity | 45.34% | Neutral |
| P/E | - | |
| P/B | 0.72 | Buy |
Latest IBIO news
About
Download (Excel)iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.